Radiation Protection Dosimetry 2011-02-01

Proton inactivation of melanoma cells enhanced by fotemustine.

Aleksandra Ristić-Fira, Lela Korićanac, Jelena Žakula, Otilija Keta, Gioacchin Iannolo, Giacomo Cuttone, Ivan Petrović

Index: Radiat. Prot. Dosimetry 143(2-4) , 503-7, (2011)

Full Text: HTML

Abstract

Response of human HTB140 melanoma cells to proton irradiation in combination with fotemustine (FM) was investigated. Effects of these agents were analysed on cell proliferation and induction of apoptosis. Cells pretreated with 100- or 250-µM of FM were irradiated in the middle of the therapeutic 62-MeV proton spread-out Bragg peak, with a dose of 16 Gy. All treatments reduced proliferation and survival of melanoma cells. The most pronounced effects of the combined treatment were obtained for cell survivals. The level of apoptosis increased after all applied treatments. Particularly good pro-apoptotic effect was achieved when proton irradiation was combined with 250 μM of FM. This was followed by the increased expression of p53 gene. The obtained results have shown that combined application of FM and protons significantly reduced growth of this resistant melanoma cell line.

Related Compounds

Related Articles:

Multiple bone metastases from glioblastoma multiforme without local brain relapse: a case report and review of the literature.

2013-01-01

[Tumori 99(5) , e237-40, (2013)]

Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma.

2013-01-01

[J. Transl. Med. 11 , 38, (2013)]

Good clinical activity and favorable toxicity profile of once weekly bortezomib, fotemustine, and dexamethasone (B-MuD) for the treatment of relapsed multiple myeloma.

2013-02-01

[Am. J. Hematol. 88(2) , 102-6, (2013)]

High activity of sequential low dose chemo-modulating Temozolomide in combination with Fotemustine in metastatic melanoma. A feasibility study.

2010-01-01

[J. Transl. Med. 8 , 115, (2010)]

Fotemustine in the treatment of brain primary tumors and metastases.

1994-01-01

[Cancer Invest. 12(4) , 414-20, (1994)]

More Articles...